Clinical trial
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in…
NCT00189137 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00189137 |
|---|---|
| Title | Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma |
| Official title | Phase II Evaluation of Ifosfamide Plus Doxorubicin & Filgrastim Versus Gemcitabine Plus Docetaxel & Filgrastim in the Treatment of Localized Poor Prognosis Soft Tissue Sarcoma |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Soft Tissue |
| Intervention type | Drug |
| Interventions | ifosfamide and doxorubicin vs gemcitabine and docetaxel |
| Enrollment | 84 |
| Start date | Aug 1, 2004 |
| Primary completion | Nov 1, 2012 |
| Completion | Oct 1, 2015 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 7, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: